Loading clinical trials...

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

NCT00889525•Seth Gordhandas Sunderdas Medical College

Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology

Exclusion Criteria

•Patient's intolerance to drug or known sensitivity to ergot derivatives
•Pregnancy, lactation or female wishing to be pregnant
•Any serious medical illness
•Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Locations (1)

Seth GSMC & KEM hospital

Mumbai, Maharashtra, India

Key Dates

Start Date

November 1, 2007

Last Updated

April 29, 2009

Conditions

Cushing's DiseaseCorticotroph Adenoma

Interventions

Cabergoline

DRUG

DDAVP for Pituitary Adenoma

NCT04569591

Cushing's DiseasePituitary Adenoma

View study

COMPLETEDNA

Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease

NCT03346954

Cushing's Disease

View study

COMPLETEDPHASE3

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions